814 related articles for article (PubMed ID: 17164953)
21. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.
Qureshi ZA; Paterson DL; Pakstis DL; Adams-Haduch JM; Sandkovsky G; Sordillo E; Polsky B; Peleg AY; Bhussar MK; Doi Y
Int J Antimicrob Agents; 2011 Jan; 37(1):26-32. PubMed ID: 21075605
[TBL] [Abstract][Full Text] [Related]
22. [Prevalence of extended-spectrum beta-lactamases in nosocomial Escherichia coli and Klebsiella spp. strains isolated from blood cultures].
Zarakolu P; Metan G; Hasçelik G; Akova M
Mikrobiyol Bul; 2007 Oct; 41(4):579-84. PubMed ID: 18173077
[TBL] [Abstract][Full Text] [Related]
23. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum β-lactamase production and its impact on outcome.
Kim SH; Kwon JC; Choi SM; Lee DG; Park SH; Choi JH; Yoo JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Ann Hematol; 2013 Apr; 92(4):533-41. PubMed ID: 23161391
[TBL] [Abstract][Full Text] [Related]
24. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital.
Souli M; Kontopidou FV; Papadomichelakis E; Galani I; Armaganidis A; Giamarellou H
Clin Infect Dis; 2008 Mar; 46(6):847-54. PubMed ID: 18269335
[TBL] [Abstract][Full Text] [Related]
25. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
26. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Lee NY; Huang WH; Tsui KC; Hsueh PR; Ko WC
Diagn Microbiol Infect Dis; 2011 May; 70(1):150-3. PubMed ID: 21398070
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species.
Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Fishman NO; Bilker WB; Mao X; Lautenbach E
Clin Infect Dis; 2005 May; 40(9):1317-24. PubMed ID: 15825035
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in a tertiary care teaching hospital in south India.
Abhilash KP; Veeraraghavan B; Abraham OC
J Assoc Physicians India; 2010 Dec; 58 Suppl():13-7. PubMed ID: 21563608
[TBL] [Abstract][Full Text] [Related]
29. Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection.
Marra AR; Pereira CA; Castelo A; do Carmo Filho JR; Cal RG; Sader HS; Wey SB
Int J Infect Dis; 2006 Jan; 10(1):56-60. PubMed ID: 16326126
[TBL] [Abstract][Full Text] [Related]
30. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
31. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
Behera B; Mathur P; Das A; Kapil A
Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
[TBL] [Abstract][Full Text] [Related]
32. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of extended-spectrum beta-lactamases.
Rodríguez-Baño J; Pascual A
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):671-83. PubMed ID: 18847405
[TBL] [Abstract][Full Text] [Related]
34. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
[TBL] [Abstract][Full Text] [Related]
35. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control.
Yu WL; Chuang YC; Walther-Rasmussen J
J Microbiol Immunol Infect; 2006 Aug; 39(4):264-77. PubMed ID: 16926972
[TBL] [Abstract][Full Text] [Related]
36. Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
Wang SS; Lee NY; Hsueh PR; Huang WH; Tsui KC; Lee HC; Wu CJ; Chang CM; Huang CC; Huang CF; Ko WC
J Microbiol Immunol Infect; 2011 Aug; 44(4):282-8. PubMed ID: 21524962
[TBL] [Abstract][Full Text] [Related]
37. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.
Goethaert K; Van Looveren M; Lammens C; Jansens H; Baraniak A; Gniadkowski M; Van Herck K; Jorens PG; Demey HE; Ieven M; Bossaert L; Goossens H
Clin Microbiol Infect; 2006 Jan; 12(1):56-62. PubMed ID: 16460547
[TBL] [Abstract][Full Text] [Related]
38. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
Akyar I
Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
[TBL] [Abstract][Full Text] [Related]
39. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan.
Liao CH; Sheng WH; Wang JT; Sun HY; Wang HK; Hsueh PR; Chen YC; Chang SC
J Microbiol Immunol Infect; 2006 Feb; 39(1):59-66. PubMed ID: 16440125
[TBL] [Abstract][Full Text] [Related]
40. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
